Prelude Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Prelude Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,928	Closed	-$129K	–	1597
2024 Q2	$129K	Hold	14,928	–	–	0.01%	1071
2024 Q1	$131K	Hold	14,928	–	–	0.01%	1176
2023 Q4	$111K	Hold	14,928	–	–	0.01%	1019
2023 Q3	$86.1K	Buy	+14,928	New	+$102K	0.01%	1004
2023 Q2	–	Sell	-14,929	Closed	-$110K	–	1413
2023 Q1	$110K	Hold	14,929	–	–	0.01%	942
2022 Q4	$99.8K	Hold	14,929	–	–	0.01%	1074
2022 Q3	$153K	Hold	14,929	–	–	0.01%	1121
2022 Q2	$182K	Sell	14,929 -2,164	-13%	-$34.2K	0.01%	1319
2022 Q1	$362K	Buy	17,093 +4,542	+36%	+$157K	0.01%	1001
2021 Q4	$755K	Buy	12,551 +11,729	+1,427%	+$877K	0.02%	764
2021 Q3	$77K	Buy	+822	New	+$110K	﹤0.01%	1523

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Prelude Capital Management's TLIS Position: Q3 2024 in Review

Prelude Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 14,928 shares — an estimated $129K sold.

Prelude Capital Management first reported a position in TLIS in Q3 2021 and held it in 11 quarters. The position peaked at $755K in Q4 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Prelude Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Prelude Capital Management sold 14,928 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $129K.
Prelude Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q3 2021 and held it in 11 quarters.
Prelude Capital Management's Talis Biomedical Corporation Common Stock position peaked at $755K in Q4 2021.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.